Promis Neurosciences Inc (TSE:PMN)’s share price traded down 8.3% on Tuesday . The company traded as low as C$0.22 and last traded at C$0.22, 155,780 shares were traded during mid-day trading. A decline of 39% from the average session volume of 254,484 shares. The stock had previously closed at C$0.24.
The company has a fifty day moving average price of C$0.22. The firm has a market cap of $65.35 million and a PE ratio of -4.78.
Promis Neurosciences (TSE:PMN) last posted its earnings results on Tuesday, May 14th. The company reported C($0.01) earnings per share for the quarter. As a group, equities analysts forecast that Promis Neurosciences Inc will post 0.06 EPS for the current year.
ProMIS Neurosciences, Inc, a development stage biotech company, discovers and develops precision medicine therapeutics for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson's disease (PD). Its proprietary target discovery engine is based on the use of two complementary techniques.
Featured Story: Beta
Receive News & Ratings for Promis Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Promis Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.